文献速递消化内镜消化道肿瘤与早癌

西方三中心复杂早期巴雷特瘤变的内镜下黏膜下剥离术:欧洲巴雷特内镜黏膜下剥离试验(E-BEST)

Complex early Barrett's neoplasia at 3 Western centers: European Barrett's Endoscopic Submucosal Dissection Trial (E-BEST).
PubMed 文献 · Gastrointest Endosc · 2017-01-31

该回顾性分析纳入2008至2016年3家三级转诊中心的143例巴雷特瘤变内镜下黏膜下剥离术,整块切除率90.8%、R0切除率79%,总体不良事件率3.5%,认为由经验丰富的术者操作时安全有效,完成30例后整块切除率趋于稳定。

要点

  • 143例巴雷特瘤变内镜下黏膜下剥离术整块切除率90.8%、R0切除率79%。
  • 总体不良事件率3.5%,其中出血1.4%、穿孔0%、狭窄2.1%。
  • 完成30例操作后整块切除率达到平台期。

核心结论

  • 在西方,内镜下黏膜下剥离术切除包括大、结节状或瘢痕病变在内的复杂巴雷特瘤变具有可行性和安全性。
  • 由经验丰富的术者操作时,该技术安全有效且不良事件率低。
  • 完成30例操作后整块切除率达到平台期。

研究设计与样本

  • 回顾性分析2008至2016年3家三级转诊中心因巴雷特瘤变行内镜下黏膜下剥离术的143例。
  • 主要终点为整块切除率和R0切除率。

主要发现

  • 平均病变大小31.1 mm(范围5-90),中位随访时间21.6个月(四分位距11.0-32.6)。
  • 24.5%(35/143)的病变在既往内镜切除、手术或放疗后留有瘢痕。
  • 整块切除率90.8%,R0切除率79%。
  • 总体不良事件率3.5%(出血1.4%、穿孔0%、狭窄形成2.1%)。
  • 扩大治愈性切除率65.8%,反映R0切除率及病变较晚期病例的比例。

关键数值与推荐

  • 黏膜下癌被确定为影响R0切除率的显著因素。

临床怎么用

  • 原文结论认为,由经验丰富的术者在西方开展内镜下黏膜下剥离术切除复杂巴雷特瘤变安全有效且不良事件率低。
  • 原文指出完成30例操作后整块切除率达到平台期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is an effective technique to resect early Barrett's neoplasia and has advantages over conventional EMR in that it enables en-bloc resection and accurate histopathologic analysis of cancer resection margins. However, its long learning curve and higher adverse event rate have tempered its uptake in the West. We aimed to analyze the safety and efficacy of ESD when used to resect complex Barrett's neoplasia. The primary endpoint was the en-bloc and R0 resection rate. METHODS: This was a retrospective analysis of 143 ESDs for Barrett's neoplasia performed in 3 tertiary referral centers from 2008 to 2016. RESULTS: The mean lesion size was 31.1 mm (range, 5-90) and median follow-up time 21.6 months (interquartile range, 11.0-32.6). In total, 24.5% of lesions (35/143) were scarred after previous endoscopic resection, surgery, or radiotherapy. The en-bloc resection rate was 90.8% and R0 resection rate 79% in this series. The overall adverse event rate was 3.5% (1.4% bleeding, 0% perforation, and 2.1% stricture formation). The expanded curative resection rate was 65.8%, reflecting the R0 resection rate and proportion of cases with more advanced disease. Submucosal cancer was identified as a significant factor affecting the R0 resection rate. CONCLUSION: We demonstrated the feasibility and safety of ESD in the West for resection of complex Barrett's neoplasia including large, nodular, or scarred lesions. This is a safe and effective technique with a low adverse event rate when performed by an experienced operator. The en-bloc resection rate reached a plateau once 30 procedures had been performed.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Subramaniam S, Chedgy F, Longcroft-Wheaton G, et al. Complex early Barrett's neoplasia at 3 Western centers: European Barrett's Endoscopic Submucosal Dissection Trial (E-BEST). Gastrointest Endosc. 2017. PMID: 28159540. doi:10.1016/j.gie.2017.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。